PatientsVille.com Logo

THROMBOCYTOPENIA and Hydrocodone

PatientsVille

THROMBOCYTOPENIA Symptoms and Causes

Platelets are little pieces of blood cells. Platelets help wounds heal and prevent bleeding by forming blood clots. Your bone marrow makes platelets. Problems can result from having too few or too many platelets, or from platelets that do not work properly.

If your blood has a low number of platelets, it is called Thrombocytopenia. This can put you at risk for mild to serious bleeding. If your blood has too many platelets, you may have a higher risk of blood clots. With other platelet disorders, the platelets do not work as they should. For example, in von Willebrand Disease, the platelets cannot stick together or cannot attach to blood vessel walls. This can cause excessive bleeding.

Treatment of platelet disorders depends on the cause.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for THROMBOCYTOPENIA

THROMBOCYTOPENIA treatment research studies

Hydrocodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Hydrocodone Side Effects

Completed Suicide (769)
Cardio-respiratory Arrest (319)
Nausea (191)
Pain (179)
Exposure Via Ingestion (173)
Toxicity To Various Agents (166)
Respiratory Arrest (164)
Cardiac Arrest (158)
Vomiting (131)
Death (129)
Dyspnoea (113)
Dizziness (105)
Headache (101)
Poisoning (98)
Anxiety (95)
Pruritus (94)
Overdose (88)
Product Substitution Issue (87)
Diarrhoea (86)
Abdominal Pain (77)
Cholecystitis Chronic (52)
Abdominal Pain Upper (52)
Depression (50)
Pulmonary Embolism (49)
Cholelithiasis (48)
Product Quality Issue (48)
Fatigue (46)
Insomnia (45)
Deep Vein Thrombosis (45)
Rash (41)
Back Pain (41)
Injury (38)
Fall (37)
Pain In Extremity (34)
Malaise (34)
Chest Pain (34)
Emotional Distress (33)
Constipation (31)
Gallbladder Disorder (30)
Arthralgia (29)
Somnolence (28)
Asthenia (28)
Oedema Peripheral (28)
Abdominal Discomfort (27)
Hyperhidrosis (27)
Feeling Abnormal (26)
Incorrect Dose Administered (25)
Dyspepsia (23)
Confusional State (22)
Urticaria (21)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

THROMBOCYTOPENIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
Conditions: Immune Thrombocytopenia;   Chemotherapy Induced Thrombocytopenia;   Myelodysplasia Related Thrombocytopenia;   Aplastic Anaemia Related Thrombocytopenia
Intervention: Other: Full blood count with extended platelet parameters
Outcome Measures: Increased platelet density;   mean platelet mass
2 Not yet recruiting Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
Conditions: Thrombocytopenia;   Primary Thrombocytopenia,Unspecified;   Thrombocytopenia Chemotherapy Induced
Intervention: Biological: Transfusion of Pooled Platelets Cryopreserved In DMSO
Outcome Measures: Efficacy of infused cryopreserved platelets (changes in platelets count will be determined at 1 hour and 24 hours post-transfusion);   Safety of cryopreserved platelets
3 Recruiting Study of Romiplostim Versus Observation for Chemotherapy Induced Thrombocytopenia
Condition: Isolated Chemotherapy-induced Thrombocytopenia
Interventions: Biological: romiplostim,;   Other: Control cohort
Outcome Measures: Achievement of platelet counts of ≥ 100,000/mcL;   the ability to complete at least two successive cycles of chemotherapy without further evidence of treatment-limiting Thrombocytopenia;   is to evaluate the proportion of patients who cross over and have a subsequent platelet recovery ≥ 100,000/mcL;   Assessment of potential toxicity
4 Recruiting Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
Conditions: Medical Patient;   Thrombocytopenia
Intervention: Drug: Fondaparinux
Outcome Measures: Major bleeding;   Clinically relevant non-major bleeding;   Minor Bleeding;   Symptomatic venous thromboembolism
5 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
Outcome Measures: Frequency and severity of adverse events;   Absolute change in platelet count from baseline
6 Recruiting A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Conditions: Alloimmune Thrombocytopenia;   Fetal Alloimmune Thrombocytopenia
Intervention: Drug: IVIG (Intravenous Immunoglobulin)
Outcome Measure: To raise the platelet count of affected fetus.
7 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platlet count);   Drug: avatrombopag (higer baseline platelet count);   Drug: placebo (higher baseline platelet count)
Outcome Measures: The proportion of subjects who require platelet transfusion or rescue therapy for bleed after randomization and up to 7 days after the elective procedure;   Proportion of subjects who achieve a platelet counts greater than or equal to 50 x 10^9/L on Procedure day;   Change from baseline of platelet counts on procedure day;   Proportion of subjects with a WHO bleeding score greater than or equal to 2 after randomization and up to 7 days after an elective procedure;   Safety of avatrombopag
8 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platlet count);   Drug: avatrombopag (higer baseline platelet count);   Drug: placebo (higher baseline platelet count)
Outcome Measures: The proportion of subjects who require platelet transfusion or rescue therapy for bleed after randomization ad up to 7 days after the elective procedure;   Proportion of subjects who achieve a platelet counts >= 50 x109/L on Procedure day;   Change from baseline of platelet counts on procedure day;   Proportion of subjects with a WHO bleeding score >= 2 after randomization and up to 7 days after an elective procedure;   Safety of avatrombopag
9 Not yet recruiting rhTPO in Critical Patients With Thrombocytopenia
Conditions: Sepsis;   Thrombocytopenia
Interventions: Drug: TPO;   Drug: control
Outcome Measures: Mortality;   Time to recover to a normal platelet level;   Occurrence of bleeding event;   7-day survival rate;   Number of Participants who survived from Thrombocytopenia;   Occurrence of platelet transfusion;   Total amount of platelet transfusion;   Percentage of participants with platelet response;   Time to platelet response
10 Recruiting Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Condition: Heparin-induced Thrombocytopenia
Intervention: Drug: Rivaroxaban
Outcome Measures: Incidence of new symptomatic venous and arterial thromboembolism in the study population.;   Incidence of symptomatic venous and arterial thromboembolism and major bleeding in patients while on-treatment with rivaroxaban.;   Duration of time to platelet recovery in patients with Serotonin Release Assay (SRA) confirmed HIT;   Incidence of venous and arterial thromboembolism in patients with SRA confirmed HIT who receive rivaroxaban.;   Major bleeding in the entire study population and in patients with SRA confirmed HIT who receive rivaroxaban.;   To collect data to prospectively validate a new clinical prediction rule for HIT
11 Recruiting Low-dose Decitabine Versus Recombinant Human Thrombopoietin for the Treatment of Refractory Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Decitabine;   Drug: rhTPO
Outcome Measures: Platelet count;   Megakaryocyte Polyploidy;   Bleeding score
12 Unknown  Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)
Condition: Heparin-Induced Thrombocytopenia
Interventions: Other: Scoring 4Ts and Chong scale;   Other: Blood draw
Outcome Measures: To validate the 4Ts as a pretest probability tool for HIT.;   To validate the Chong scale as a tool to determine the post-test probability for HIT.;   To determine the inter-rater variability for scoring the 4Ts.;   To determine the inter-rater variability for scoring the Chong scale.
13 Recruiting The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention:
Outcome Measures: Evaluation of platelet response (Complete Response);   Evaluation of platelet response (R);   Evaluation of platelet response (No Response);   Macrophage Function
14 Unknown  Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Conditions: Septic Shock;   Thrombocytopenia;   Multiple Organ Failure
Intervention:
Outcome Measure:
15 Recruiting The ITP-RITUX Cohort: Rituximab in Immune Thrombocytopenia.
Conditions: Purpura, Thrombocytopenic, Idiopathic;   Autoimmune Thrombocytopenia
Intervention:
Outcome Measures: Occurrence of a serious adverse events (clinical or biological events);   Impact of rituximab on the natural history of ITP;   Modality of the administration of rituximab;   Characteristics of the patients receiving Rituximab;   Evaluation of the Platelet count evolution;   Rate of splenectomy in the cohort
16 Recruiting TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.
Conditions: Adult Patients;   Immune Primary Thrombocytopenia;   Splenectomy;   TPO-mimetics
Intervention:
Outcome Measures: Number of patients responding to TPO-mimetics;   Number of patients on TPO-mimetics eltrombopag and romiplostim as bridge therapy before splenectomy.;   Frequency and ways of administration.;   Number of hemorrhagic events.;   Frequency of toxicity.
17 Recruiting Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
Conditions: Idiopathic Thrombocytopenic Purpura;   Thrombocytopenia;   Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP);   Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP);   Thrombocytopenic Purpura;   Immune Thrombocytopenia
Interventions: Drug: romiplostim;   Drug: Placebo
Outcome Measures: incidence of durable platelet response defined as achieving at least 6 weekly platelet counts of ≥ 50 x 10^9/L during weeks 18 through 25 of treatment;   incidence of overall platelet response defined as subjects who achieve a platelet count ≥ 50 x 10^9/L at a minimum of 4 times during weeks 2 to 25 of the treatment period;   number of weekly platelet counts ≥ 50 x 10^9/L during weeks 2 to 25 of the treatment period;   incidence of rescue ITP medications used;   number of composite bleeding episodes defined as clinically significant bleeding events or the use of a rescue medication to prevent a clinically significant bleeding event during weeks 2 to 25 of the treatment period;   incidence of adverse events, including thromboembolic events and hematologic malignancies, clinically significant changes in laboratory values and the incidence of antibody formation
18 Recruiting Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
Conditions: Wiskott-Aldrich Syndrome;   Thrombocytopenia;   Bleeding
Interventions: Drug: Promacta (eltrombopag);   Drug: Eltrombopag/promacta
Outcome Measures: To increase platelet counts of WAS and XLT patients to above 30,000/ul.;   To describe the pathophysiology of Thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
19 Recruiting An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Drug: Dexamethasone
Outcome Measures: Proposed criteria for assessing early response to ITP treatments;   Safety
20 Recruiting A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura
Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Outcome Measures: the subject incidence and exposure adjusted incidence of adverse events, including clinically significant changes in laboratory values and incidence of antibody formation.;   Platelet response to romiplostim defined as platelet counts 50x109/L in the absence of rescue medication.;   The prevalence of concurrent ITP therapy use over time (corticosteroids, danazol, azathioprine, etc.).